Log in

OTCMKTS:GNMSFGenmab A/S News Headlines

$212.50
+22.75 (+11.99 %)
(As of 04/7/2020 07:34 AM ET)
Add
Compare
Today's Range
$207.54
Now: $212.50
$215.25
50-Day Range
$159.80
MA: $212.42
$250.15
52-Week Range
$159.45
Now: $212.50
$250.15
Volume4,953 shs
Average Volume1,956 shs
Market Capitalization$13.11 billion
P/E Ratio42.16
Dividend YieldN/A
Beta0.41

Headlines

Genmab A/S (OTCMKTS GNMSF) News Headlines

Source:
DateHeadline
Is Now The Time To Put Genmab (CPH:GMAB) On Your Watchlist?Is Now The Time To Put Genmab (CPH:GMAB) On Your Watchlist?
finance.yahoo.com - February 26 at 6:20 AM
Genmab A/S (GMAB) Q4 2019 Earnings Call TranscriptGenmab A/S (GMAB) Q4 2019 Earnings Call Transcript
www.fool.com - February 19 at 11:07 PM
Genmab A/S 2019 Q4 - Results - Earnings Call PresentationGenmab A/S 2019 Q4 - Results - Earnings Call Presentation
seekingalpha.com - February 19 at 2:51 PM
European advisory group backs expanded label for J&Js DarzalexEuropean advisory group backs expanded label for J&J's Darzalex
seekingalpha.com - October 18 at 11:09 AM
What Should Investors Know About The Future Of Genmab A/S's (CPH:GMAB)?What Should Investors Know About The Future Of Genmab A/S's (CPH:GMAB)?
finance.yahoo.com - August 14 at 5:19 PM
Genmab up 2% in Europe on Q2 Darzalex salesGenmab up 2% in Europe on Q2 Darzalex sales
seekingalpha.com - July 16 at 10:28 AM
Janssen files U.S. application for subcutaneous DarzalexJanssen files U.S. application for subcutaneous Darzalex
seekingalpha.com - July 12 at 4:51 PM
Genmab teams up with BliNK Biomedical to develop bispecific antibodiesGenmab teams up with BliNK Biomedical to develop bispecific antibodies
seekingalpha.com - July 12 at 10:20 AM
J&Js Darzalex shows treatment effect in mid-stage study in certain MM patientsJ&J's Darzalex shows treatment effect in mid-stage study in certain MM patients
seekingalpha.com - July 8 at 4:56 PM
BlackRock cuts stake in GenmabBlackRock cuts stake in Genmab
seekingalpha.com - June 25 at 5:16 PM
Genmab A/S 2019 Q1 - Results - Earnings Call SlidesGenmab A/S 2019 Q1 - Results - Earnings Call Slides
seekingalpha.com - May 13 at 5:38 PM
Why Earnings Season Could Be Great for Genmab (GNMSF)Why Earnings Season Could Be Great for Genmab (GNMSF)
finance.yahoo.com - May 13 at 5:38 PM
Global Blood (GBT) Reports Narrower-Than-Expected Loss in Q1Global Blood (GBT) Reports Narrower-Than-Expected Loss in Q1
www.msn.com - May 10 at 5:18 PM
Amicus' (FOLD) Earnings & Revenues Miss Estimates in Q1Amicus' (FOLD) Earnings & Revenues Miss Estimates in Q1
finance.yahoo.com - May 9 at 5:24 PM
What's in the Cards for AcelRx (ACRX) This Earnings Season?What's in the Cards for AcelRx (ACRX) This Earnings Season?
finance.yahoo.com - May 7 at 5:28 PM
Seattle Genetics Adcetris Progresses Well Amid CompetitionSeattle Genetics' Adcetris Progresses Well Amid Competition
finance.yahoo.com - April 11 at 11:49 AM
Seattle Genetics Closes Enrollment in Cervical Cancer StudySeattle Genetics Closes Enrollment in Cervical Cancer Study
finance.yahoo.com - April 1 at 11:31 AM
Janssen submits Type II variation application to EMAJanssen submits Type II variation application to EMA
seekingalpha.com - March 22 at 10:40 AM
Vertex's Orkambi Wins EU Nod to Treat Cystic Fibrosis in KidsVertex's Orkambi Wins EU Nod to Treat Cystic Fibrosis in Kids
finance.yahoo.com - January 22 at 4:47 PM
Genmab (GNMSF) Presents At 37th Annual J.P. Morgan Healthcare Conference - SlideshowGenmab (GNMSF) Presents At 37th Annual J.P. Morgan Healthcare Conference - Slideshow
seekingalpha.com - January 10 at 10:44 AM
This page was last updated on 4/7/2020 by MarketBeat.com Staff

Featured Article: Risk Tolerance

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel